Cerenome
Diagnostic testing and targeted radiotherapy development for central nervous system cancers.
Something off on this page? Send us feedback.
Profile
Provides CNSide cerebrospinal-fluid cancer testing and is developing REYOBIQ targeted radiotherapy for central nervous system tumors. The integrated model pairs diagnostics, clinical development and an emerging data and AI layer, with revenue shaped by grant funding, reimbursement and future regulatory outcomes.
Combines CNSide, a cerebrospinal-fluid diagnostic testing service for detecting and characterizing tumor cells in leptomeningeal metastases, with REYOBIQ, an investigational injectable radiotherapeutic for CNS tumors. CNSide is ordered by U.S. healthcare professionals through a Houston laboratory, while REYOBIQ is being studied for leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers.
Builds a data and AI initiative intended to connect diagnostic, molecular, imaging and clinical data for precision-oncology workflows and therapeutic development. Revenue currently includes grant reimbursement and prospective diagnostic collections; therapeutic revenue depends on clinical results and approval. Operations are U.S.-centered and depend on test ordering, reimbursement, laboratory licensing, outside manufacturing and continued financing.
Company facts
Key statistics
Year to date −24.9% · Average volume (30d) 73.8K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.88 | −$1.31 | −48.9% | $1.1M | $411.0K | −63.1% | −13.04% |
| Aug 13, 2026Q2 FY26 | −$0.96 | −$1.31 | −36.5% | $1.1M | $411.0K | −63.1% | −0.54% |
| May 15, 2026Q1 FY26 | −$0.85 | −$1.05 | −23.8% | $974.0K | $1.0M | +5.5% | — |
| Mar 12, 2026Q4 FY25 | −$0.80 | −$0.83 | −4.2% | $1.2M | $1.4M | +10.6% | — |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.4M | $1.4M | $1.4M | $1.0M | $411.0K | |
| Gross profit | $878.0K | $1.3M | $1.3M | $1.3M | $919.0K | $260.0K | |
| Operating income | −$3.5M | −$1.5M | −$4.5M | −$5.7M | −$7.1M | −$9.1M | |
| Net income | −$17.4M | $5.2M | −$4.4M | −$5.7M | −$6.9M | −$9.0M | |
| Diluted EPS | −$29,750.00 | −$162.50 | −$1.00 | −$1.05 | −$1.05 | −$1.33 | |
| Gross margin | 82.9% | 93.8% | 93.8% | 93.3% | 89.4% | 63.3% | |
| Operating margin | -333.9% | -110.6% | -320.8% | -420.0% | -692.5% | -2,203.6% |
Fiscal years (4-quarter sums)FY24 $5.8M · FY25 $5.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $8.6M · Total debt $44.0K · Total assets $14.0M · Shareholders' equity $5.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 6.88M · Float 6.81M
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- NeoGenomics
Specialized molecular oncology testing contests CNSide's ordering access.
- Novocure
Optune Gio is an established alternative in recurrent glioblastoma.
- Quest Diagnostics
Oncology liquid-biopsy services compete for testing access.
- Telix Pharmaceuticals
TLX101-Tx contests radiopharmaceutical treatment of recurrent GBM.
- Labcorp
National oncology specialty testing contests CNSide laboratory access.
- Kazia Therapeutics (ADR)
Paxalisib competes across GBM and CNS-metastases development.
- CNS Pharmaceuticals
Berubicin directly targets the recurrent glioblastoma treatment set.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cerenome | $3.05 | +0.33% | $21.0M | — | — | 5.0 | — |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Novocure | $17.66 | −0.95% | $2.08B | — | — | 3.0 | +15.6% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Telix Pharmaceuticals | $11.29 | +0.18% | $3.82B | 113.3 | — | 4.0 | +22.8% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Kazia Therapeutics (ADR) | $13.92 | +2.00% | $22.0M | — | — | 1,557.7 | — |
| CNS Pharmaceuticals | $5.75 | +4.11% | $8.1M | — | — | — | — |
| Median | 27.7 | 21.2 | 2.6 | +11.2% |